{"schema_version":"1","generated_at":"2026-11-21T20:45:13.017Z","data_as_of":null,"url":"https://www.findmykol.com/kol/lester-porter","json_url":"https://www.findmykol.com/kol/lester-porter/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"lester-porter","name":"Lester Porter","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Tennessee Oncology","institution_url":"https://www.findmykol.com/institution/tennessee-oncology","city":"Nashville","state":"TN","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"on_file":["npi","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Lester Porter is an Oncology physician affiliated with Tennessee Oncology. OpenAlex indexes 8 publications with 2,849 citations (h-index 8).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":8,"cited_by_count":2849,"h_index":8,"latest_activity_year":2024,"source":"works"},"payments":{"company_count":10,"program_years":{"first":2021,"last":null},"rows_total":11,"shown":3,"withheld":8,"rows":[{"payer":"ABBVIE INC.","program_year":2024,"amount_usd":19.34,"payment_count":1},{"payer":"Eisai Inc.","program_year":2023,"amount_usd":30.85,"payment_count":1},{"payer":"Merck Sharp & Dohme LLC","program_year":2023,"amount_usd":28.22,"payment_count":1}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":1,"areas_shown":1,"areas":[{"area":"Sensory organs","share_pct":100,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"administered","share_pct":100,"drugs":[{"name":"Dexamethasone sodium phosphate","share_pct":100}],"max_beneficiaries":11}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":8,"shown":5,"withheld":3,"matched_by":"OpenAlex author record","recent":[{"title":"Epoetin Alfa 60,000 U Once Weekly Followed by 120,000 U Every 3 Weeks Increases and Maintains Hemoglobin Levels in Anemic Cancer Patients Undergoing Chemotherapy","year":2004,"journal":"The Oncologist","source_url":"https://doi.org/10.1634/theoncologist.2004-0090","status":"verified"},{"title":"Gefitinib in the Treatment of Advanced, Refractory Non–Small-Cell Lung Cancer: Results in 124 Patients","year":2003,"journal":"Clinical Lung Cancer","source_url":"https://doi.org/10.3816/clc.2003.n.014","status":"verified"},{"title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","year":2001,"journal":"Cancer","source_url":"https://doi.org/10.1002/1097-0142(20010401)91:7<1191::aid-cncr1119>3.0.co;2-0","status":"verified"},{"title":"A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non–small-cell lung cancer (a Vanderbilt cancer center affiliate network study)","year":2000,"journal":"International Journal of Radiation Oncology*Biology*Physics","source_url":"https://doi.org/10.1016/s0360-3016(00)00420-x","status":"verified"},{"title":"Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma","year":1996,"journal":"New England Journal of Medicine","source_url":"https://doi.org/10.1056/nejm199602223340802","status":"verified"}],"source":"works"},"similar":[{"name":"Ian Flinn","slug":"ian-flinn","institution":"Tennessee Oncology","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/ian-flinn","json_url":"https://www.findmykol.com/kol/ian-flinn/profile.json"},{"name":"Kent Shih","slug":"kent-shih","institution":"Tennessee Oncology","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/kent-shih","json_url":"https://www.findmykol.com/kol/kent-shih/profile.json"},{"name":"Gina Vaccaro","slug":"gina-vaccaro","institution":"Tennessee Oncology","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/gina-vaccaro","json_url":"https://www.findmykol.com/kol/gina-vaccaro/profile.json"},{"name":"Wade Iams","slug":"wade-iams","institution":"Tennessee Oncology","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/wade-iams","json_url":"https://www.findmykol.com/kol/wade-iams/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":8,"publications":3}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}